Q-omics provides the consensus-scored CD99 profile across patient tissues and cancer cell-line models. CD99 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CD99 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CD99 protein abundance shows 23,599 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where CD99 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD99 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD99 survival associations across molecular data types. CD99 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD99 RNA expression–survival associations across cancer types. High CD99 expression shows unfavorable associations in ACC, KIRP, BLCA and LGG, but favorable associations in UVM and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CD99 RNA expression.
This table summarizes CD99 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CD99. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD99 shows lower tumor expression in KICH, UCEC and BLCA and higher tumor expression in KIRC, LIHC and HNSC. The KIRC box plot shows higher CD99 RNA expression in tumor versus normal tissue (log2 FC = +1.589, t-test p < 0.001).
This table shows molecular features associated with CD99 in patient tissues and cancer cell lines. In patient samples, CD99 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD99 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
